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S U M M A R Y
Post-inﬂuenza bacterial pneumonia is a major cause of morbidity and mortality associated with both
seasonal and pandemic inﬂuenza virus illness. However, despite much interest in inﬂuenza and its
complications in recent years, good clinical trial data to inform clinicians in their assessment of
treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve
guidance on the management of post-inﬂuenza bacterial pneumonia. The objectives of the current
article are to evaluate the emergence of the 2009 H1N1 inﬂuenza pandemic and use this information as
background for an in-depth review of the epidemiology of bacterial pneumonia complicating inﬂuenza,
to review the bacterial pathogens most likely to be associated with post-inﬂuenza bacterial pneumonia,
and to discuss treatment considerations in these patients. When determining optimal management
approaches, both antiviral and antibacterial agents should be considered, and their selection should be
based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of
post-inﬂuenza acute bacterial pneumonia.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Inﬂuenza is highly contagious and constitutes a signiﬁcant
public health problem due to its rapid transmission and the high
associated morbidity and mortality. Complicated inﬂuenza
infection frequently manifests as primary viral pneumonia,
combined viral and bacterial pneumonia, and secondary bacterial
pneumonia.1
Primary inﬂuenza pneumonia, caused by direct infection of the
lung parenchyma by the inﬂuenza virus, is the least common of the
pneumonic complications and has a mortality rate of 10–20%.
Presentation is often abrupt and dramatic, progressing within 24 h
to severe pneumonia with respiratory failure and shock. Non-fatal
cases recover 5–16 days after pneumonia onset, but residual lung
damage is frequent. Combined viral–bacterial pneumonia is at least
three times more common than viral pneumonia, from which it is
clinically indistinguishable, and presents a mortality of about 10%.
Its diagnosis requires isolation of pathogenic bacteria. Secondary
bacterial pneumonia, with a mortality rate of approximately 7%, may* Corresponding author. Tel.: +1 860 679 3582; fax: +1 860 679 1103.
E-mail address: Metersky@nso.uchc.edu (M.L. Metersky).
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as patients typically improve as expected and then deteriorate with
symptoms or signs suggestive of bacterial pneumonia, including
chills, rigors, increased productive cough, pleuritic chest pain, and
dyspnea.1
In 2009, a novel inﬂuenza virus A (H1N1) began circulating in
the Northern Hemisphere.2,3 Within months, this virus had spread
to multiple countries around the globe, prompting the World
Health Organization (WHO) to proclaim a pandemic.4 The
inﬂuenza virus A (H1N1) was determined to be largely of swine
origin, although it contained genetic sequences found in swine,
avian, and human inﬂuenza variants, thus being antigenically
distinct from other recently circulating human or swine H1N1
viruses.5
Respiratory illness caused by the 2009 H1N1 virus was
generally acute and self-limited. However, rates of respiratory
disease and pneumonia were atypical, with the highest attack rates
seen among children and young adults. Persons over the age of 60
were less likely to experience illness and death, presumably due to
exposure to antigenically similar viruses earlier in life.6 Risk factors
associated with severe disease included the usual underlying
conditions known to predispose to complications from seasonal
inﬂuenza with the additional identiﬁcation of pregnancy, obesityses. Published by Elsevier Ltd. All rights reserved.
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cases were generally the result of diffuse viral pneumonitis
progressing to acute respiratory distress syndrome (ARDS), with
bacterial pneumonia noted in pathologic specimens in about a
third of cases.8–10 In contrast, in previous inﬂuenza pandemics, the
majority of deaths likely resulted directly from secondary bacterial
pneumonia caused by common upper respiratory tract bacteria.11
Post-inﬂuenza bacterial pneumonia continues to play a
signiﬁcant role in the morbidity and mortality associated with
both seasonal and pandemic inﬂuenza virus illness. This article
intends to review the epidemiology, microbiology, and treatment
considerations in bacterial pneumonia associated with inﬂuenza.
2. The epidemiology of bacterial pneumonia complicating
inﬂuenza
The answers to several important epidemiologic questions about
bacterial pneumonia occurring as a complication of inﬂuenza can
help inform clinicians in their efforts to care for patients with
suspected or proven bacterial pneumonia during inﬂuenza season.
2.1. Morbidity and mortality from post-inﬂuenza bacterial
pneumonia
Data from a variety of sources going back to the pandemic of
1918–19 provide insight into the issue of morbidity and mortality.
Many clinicians are familiar with the descriptions of previously
healthy young individuals becoming acutely ill and dying within
hours of what was likely overwhelming viral pneumonia and
ARDS: ‘‘Two hours after admission they have the Mahogany spots
over the cheek bones, and a few hours later you can begin to see the
Cyanosis extending from their ears and spreading all over the face,
until it is hard to distinguish the coloured men from the white’’.12
Autopsy and epidemiological studies suggest that while this
type of devastating clinical course did occur, the majority of deaths
during the 1918–19 pandemic were due to secondary bacterial
pneumonia. Many autopsy studies of inﬂuenza-related death were
published during the years following the pandemic,11,13 and a
recent review of these studies reported that over 90% of lung tissue
cultures from over 3000 autopsies grew a bacterial pulmonary
pathogen.11 Recent re-examination of 58 re-cut lung specimens
from autopsy samples showed that nearly all were fully consistent
with bacterial pneumonia, either alone or superimposed on viral
pneumonia.11
Epidemiologic evidence also suggests that mortality during the
1918–19 pandemic was mostly due to bacterial pneumonia.
Figure 1 shows that age-speciﬁc rates of death correlated with the
incidence of pneumonia rates, and not with the rate of inﬂuenza
cases.13 The length of time between the onset of illness and death
also suggests a bacterial cause for many, if not most, cases during
this pandemic (Figure 2). Several studies demonstrated a median
time to death of 7–10 days, which is less suggestive of a rapidly
progressive, purely viral process.13
Studies done during the 1957–58 inﬂuenza pandemic revealed
that 70–80% of the patients who required admission to the hospital
for inﬂuenza-related complications or who died had bacterial
pneumonia.14–16 During the 2009 H1N1 inﬂuenza A pandemic, a
different pattern emerged: in most patients, severe illness or death
due to 2009 H1N1 inﬂuenza A did not occur concurrently with
bacterial infection. Of the 77 postmortem lung specimens from US
fatal cases of 2009 H1N1 inﬂuenza A submitted to the Centers for
Disease Control and Prevention (CDC), only 22 (29%) demonstrated
evidence of bacterial infection.17 In another review of a large
number of hospitalized and fatal cases in California, clinical
evidence of bacterial pneumonia was detected in only 4% of 1088
cases,18 and none of 10 intensive care patients in Michigan hadbacterial co-infection.19 Among over 700 patients admitted to
intensive care units in Australia and New Zealand with complica-
tions of the 2009 H1N1 inﬂuenza A, only 20% were thought to have
secondary bacterial pneumonia.20 The nearly universal use of
antimicrobial agents in inﬂuenza patients with severe respiratory
illness certainly means that cases of bacterial pneumonia were
missed. Although the absolute numbers are relatively small, the
CDC have released data from Denver demonstrating an increase in
invasive pneumococcal disease during the peak of the pandemic in
October 2009.21 Nonetheless, at the present time, available
evidence suggests that the novel H1N1 pandemic may have been
unique in resulting in more cases of progressive viral pneumonia or
ARDS than bacterial pneumonia.
2.2. Risk of bacterial pneumonia in patients with inﬂuenza
Several clinical trials investigating the efﬁcacy of neuramini-
dase inhibitors (NAIs) provide the most reliable estimates
regarding the frequency at which bacterial pneumonia complicates
inﬂuenza. Because no detailed clinical data are available from these
studies, we have to make the likely accurate assumption that the
majority of patients who were diagnosed with pneumonia had
bacterial pneumonia. If data from three studies of zanamivir and
oseltamivir, which enrolled predominantly low-risk young adults,
are pooled, two of 379 patients (0.5%) with conﬁrmed inﬂuenza
who received placebo were diagnosed with pneumonia.22–24 In
another pooled analysis, the pneumonia rate among the elderly
and adults with comorbidities was 2.5% among patients taking
placebo.25 In these studies, NAIs appeared to have a protective
effect, although the numbers were not large enough to derive the
magnitude of beneﬁt.
Similar ﬁndings were reported in a national survey of infectious
disease specialists, which showed a 1.6% rate of bacterial
complications of inﬂuenza during the 2003–2004 season.26 There
are fewer reliable data regarding the rate of post-inﬂuenza
bacterial pneumonia during pandemic years. However, surveys
of households across the USA during the 1918–19 pandemic
suggested a 6.1% risk of pneumonia among inﬂuenza cases.27
2.3. Age distribution of post-inﬂuenza bacterial pneumonia
During non-pandemic years and most pandemic years, the age
distribution of severe inﬂuenza-related morbidity and mortality
(which generally reﬂects bacterial pneumonia rates) exhibits a U-
shaped pattern, with infants and the elderly most frequently
affected. Hospitalization rates in Houston showed this phenome-
non during the non-pandemic inﬂuenza season of 1976,28 and data
from the 1957 pandemic and two non-pandemic years shortly
thereafter demonstrated the same pattern.29
The 1918–19 pandemic showed a different pattern, with a W-
shaped age distribution, caused by an unusually high death rate
among young adults in addition to infants and the elderly. In
subsequent non-pandemic years, the age distribution shifted back
to what is usually seen (Figure 3).30 The 2009 pandemic
demonstrated a pattern different from that previously seen, with
morbidity and mortality from severe disease occurring most
frequently in young adults (Figure 4).31 As already noted, in this
pandemic, severe respiratory disease may have been less
commonly due to bacterial pneumonia than in prior years.
2.4. Other demographic risk factors for post-inﬂuenza pneumonia
During the 1918–19 pandemic, people living under lower
socioeconomic conditions had higher rates of severe morbidity and
mortality, and throughout the world, indigenous peoples fared
worse. For example, a study from Norway demonstrated that the
Figure 1. (A) Estimated age group-speciﬁc inﬂuenza case rates. (B) Estimated age group-speciﬁc pneumonia rates and mortality rates, based on household surveys of 10
communities throughout the USA.13 (Reproduced with permission from the reference cited.).
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smaller homes than for those of a higher social status.32 Data from
the USA suggesting lower rates of death among blacks is likely due
to incomplete data collection among that population.27
While it is difﬁcult to distinguish between the confounding
effects of age and comorbidities on post-inﬂuenza outcomes,
underlying heart and pulmonary disease appear to be independent
risk factors for inﬂuenza-related bacterial pneumonia. A study
focusing on women of child-bearing age (15–44 years) demon-
strated a signiﬁcantly increased risk of inﬂuenza-related cardio-
pulmonary hospitalization or death among those with chronic
lung, heart, or kidney disease, diabetes mellitus, malignancy, orimmunosuppressive disease.33 In one study during the 1968–69
pandemic, approximately three-quarters of the patients admitted
to the hospital with pneumonia had underlying chronic medical
conditions,34 while in another large cohort study, a history of heart
or lung disease, diabetes mellitus, rheumatologic disease, renal
disease, or dementia/stroke predicted an increased risk of
pneumonia and inﬂuenza-related hospitalization.35
Pregnancy has long been recognized as a risk factor for
inﬂuenza-related morbidity and mortality, with studies from the
1918–19 and 1957 pandemics documenting increased risk of
pneumonia and inﬂuenza-related death among pregnant wom-
en.36 More recent data have indicated that women in any trimester
Figure 2. Cumulative percentage deaths from inﬂuenza–pneumonia by days (estimated) from illness onset, among fatal cases during various epidemics, 1918–1919. Vertical
arrows indicate median number of days to death.13 (Reproduced with permission from the reference cited.).
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hospitalization or death compared with non-pregnant women.33
While much of the pneumonia complicating inﬂuenza during
pregnancy is viral, there is a signiﬁcant incidence of bacterial
pneumonia. Reports from the 1957 pandemic highlighted the
importance of Staphylococcus aureus, Streptococcus pneumoniae,
Klebsiella sp, and other Gram-negative bacilli.37 Several reports
concerning the 2009 H1N1 inﬂuenza pandemic have described
serious complications, including mortality from pneumonia. This
was often due to viral pneumonia, but bacterial pneumonia (both
‘community-acquired’ and nosocomial) was also described.38–42
In summary, the incidence of bacterial pneumonia is generally
lower among previously healthy individuals who develop inﬂuen-
za, while the rate is likely higher among the elderly and the
chronically ill. Overall, individuals with comorbidities, pregnant
women, infants, and the elderly are at increased risk of post-
inﬂuenza bacterial pneumonia.Figure 3. Age-speciﬁc inﬂuenza-associated mortality in Breslau, from July 19183. Microbiology of post-inﬂuenza bacterial pneumonia
One of the earliest microbiological reports on bacterial
pneumonia as a complication of inﬂuenza came from Germany
in 1890, during the 1889–1893 Russian pandemic. The author
described 45 patients with pneumonia in which he found
streptococci as the pathogens leading to death in seven patients.43
Several publications with low numbers of cases from the 1918–
19 Spanish H1N1 pandemic are available that provide microbio-
logical results from respiratory samples, as well as from postmor-
tem lung tissue or heart blood cultures.44–46 One analysis of 96
postmortem cultures of lung tissue and other published sources on
this pandemic found that S. pneumoniae, Streptococcus hemolyticus,
and S. aureus were the most common pathogens and responsible
for the majority of lethal courses (Table 1).11 Notable aspects of
1918–1919 inﬂuenza-associated pneumonia fatalities included a
high incidence of secondary pneumonia associated with standard to April 1922.30 (Reproduced with permission from the reference cited.).
Figure 4. Percentage distribution of deaths from severe pneumonia during the 2009
study period, as compared with inﬂuenza seasons from 2006 through 2008, in
Mexico, according to age group.31 (Reproduced with permission from the reference
cited.).
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caused by both mixed pneumopathogens and by other mixed
upper respiratory tract bacteria; and the aggressiveness of
bacterial invasion of the lung, often resulting in ‘phenomenal’
numbers of bacteria and polymorphonuclear neutrophils, as well
as extensive necrosis, vasculitis, and hemorrhage.11 Overall,
pathologic, demographic and epidemiologic evidence was consis-
tent in indicating that bacterial pneumonia, rather that primary
viral pneumonia, was the cause of most deaths during the 1918–19
pandemic.11,13
Microbiological reports on bacterial complications in some
inﬂuenza epidemics of the ﬁrst half of the last century in London47
and Boston48 showed the dominant role of pneumococci,
particularly in Boston, but S. aureus was also identiﬁed as a
leading pathogen. In 66 cases of S. aureus infections of the lung, 11
had positive blood cultures and four of these patients died. The
mortality rate for post-inﬂuenza S. aureus infections was high
(32%).
In an analysis of 91 patients with post-inﬂuenza pneumonia
during the 1957–58 Asian inﬂuenza epidemic, S. pneumoniae was
found to be the leading pathogen among those with positive
microbiological results, followed by Haemophilus inﬂuenzae and S.
aureus.49 Postmortem ﬁndings of 33 fatal cases in Cleveland duringTable 1
Bacterial culture results in autopsy series from victims of the 1918–1919 inﬂuenza pa
Type of autopsy series Number (%) of cultures from which
Number
of results
Streptococcus
pneumoniae
Streptococcus
hemolyticus
Staphy
aureus
All military (n = 60) 3515 855 (24.3) 615 (17.5) 263 (7
All civilian (n = 36) 1751 380 (21.7) 281 (16.0) 164 (9
All military and civilian (n = 96) 5266 1235 (23.5) 896 (17.0) 427 (8
All higher-quality military
and civilianb (n = 68)
3074 712 (23.2) 553 (18.0) 238 (7
Predominance of pneumopathogens
not conﬁrmed (n = 14)
1115 209 (18.7) 132 (11.8) 52 (4
Blood culture (n = 42); all military
and civilian
1887 509 (27.0) 377 (20.0) 68 (3
Pleural/empyema ﬂuid culture
(n = 35); all military and civilian
1245 263 (21.1) 539 (43.3) 59 (4
Bold type indicates greatest percentage.
a Bacteria are listed by their common names in 1918. Streptococcus hemolyticus probabl
Staphylococcus aureus from Staphylococcus albus, but in some cases observers noted o
pathogenic organism. Diplococcus intracellulare meningitidis corresponds to Neisseria me
b A higher quality series was deﬁned as a series in which lung tissue culture results repo
the bacterial components of mixed culture results.the same epidemic revealed S. aureus to be the most prevalent
pathogen, followed by S. pneumoniae and H. inﬂuenzae.16
During the 1968–69 Hong Kong pandemic, the inﬂuenza A Hong
Kong/68-virus was isolated from 127 adult patients at the Mayo
Clinic.50 The course of inﬂuenza was complicated by lower
respiratory tract involvement in 20 patients, and signiﬁcant
chronic illness preceded inﬂuenza in 14 patients (70%) in this
group. The manifestations of pulmonary involvement ranged from
minimal roentgenographic evidence of pneumonitis to fulminating
and rapidly fatal hemorrhagic pneumonia. Pneumonia was
documented roentgenographically in 17 cases and at autopsy in
three cases. The overall mortality for inﬂuenza complicated by
pneumonia was 40% (eight of 20 cases), with seven of the eight
fatalities occurring in patients with serious chronic diseases.
Culture for pathogenic bacteria was undertaken in 79 cases, and
potential bacterial pathogens were isolated from 13 (16%) of these
patients. These included S. pneumoniae in ﬁve cases, Streptococcus
pyogenes in four cases, and S. aureus in one case. In three cases,
combinations of S. pneumoniae, S. pyogenes, and S. aureus were
isolated. In Atlanta, the pathogen most frequently identiﬁed during
the Hong Kong pandemic was S. aureus.51
The 2003–2004 inﬂuenza season began in the USA unusually
early, with activity ﬁrst being reported in October 2003. Inﬂuenza
A (H3N2) viruses circulated widely and were among those most
predominantly identiﬁed throughout the season.26 Seasons in
which H3N2 viruses are most prevalent are associated with higher
numbers of patient hospitalizations compared with seasons in
which inﬂuenza A (H1N1) or inﬂuenza B viruses are most
common.52 During the 2003–2004 season, the CDC conducted a
survey among infectious diseases consultants in the USA to obtain
estimates of the rates of severe late complications and to assess the
impact of early seasonal activity on the availability of inﬂuenza
vaccine and diagnostic tests.26 In total, 7550 laboratory-conﬁrmed
cases of inﬂuenza among children and 6010 adult cases were
reported. Secondary bacterial infections occurred in 151 children
and 97 adults. Almost one-half (48%) of adults with secondary
bacterial infections required mechanical ventilation, and 17 adult
patients (18%) with bacterial complications died. The most
frequently recognized pathogen was S. aureus, while S. pneumoniae
was the most commonly identiﬁed pathogen in pediatric patients
(Table 2). The majority of S. aureus isolates in both children and
adults were methicillin-resistant S. aureus (MRSA). The increasing
signiﬁcance of MRSA as a pathogen inducing post-inﬂuenza
community-acquired pneumonia has been conﬁrmed in a morendemic11 (reproduced with permission from the reference cited)
 organism was recovered (by organism)a
lococcus Diplococcus
intracellulare
meningitidis
Mixed
pneumopathogens
Bacillus
inﬂuenzae
Other
bacteria
No growth
.5) 40 (1.1) 707 (20.1) 387 (11.0) 484 (13.8) 164 (4.7)
.4) 1 (<0.1) 398 (22.7) 132 (7.5) 339 (19.4) 56 (3.2)
.1) 41 (0.8) 1105 (21.0) 519 (9.9) 823 (15.6) 220 (4.2)
.7) 21 (0.7) 828 (26.9) 144 (4.7) 353 (11.5) 225 (7.3)
.7) 0 (0.0) 24 (2.2) 210 (18.8) 402 (36.1) 86 (7.7)
.6) 5 (0.3) 28 (1.5) 61 (3.2) 278 (14.7) 561 (29.7)
.7) 0 (0.0) 74 (5.9) 21 (1.7) 45 (3.6) 244 (19.6)
y corresponds to Streptococcus pyogenes in most cases; most observers distinguished
nly ‘Staphylococcus’, which was categorized as ‘aureus’ if the context suggested a
ningitidis. Bacillus inﬂuenzae corresponds to Haemophilus inﬂuenzae.
rted, for all autopsies, both the presence and absence of negative culture results and
Table 2
Frequency of pathogens associated with secondary bacterial infection, severe
outcomes, and deaths among pediatric and adult patients with laboratory-
conﬁrmed inﬂuenza as reported by Emerging Infection Network members 200326
(reproduced with permission from the reference cited)
Variable Number (%) of patients
Pediatric patientsa
(n = 7550)
Adult patients
(n = 6010)
Death 18 (0.2) 34 (0.6)
Hospitalization
All 1258 (16.7) 959 (16.0)
Required intubation 113 (9.0) 125 (13.0)
Encephalopathy 39 (0.5) NA
Secondary bacterial infectionb
All 151 (2.0) 97 (1.6)
Staphylococcus aureus
All strains 13 (8.6) 31 (32.0)
MRSA 7 (53.8) 24 (77.4)
Group A streptococci 2 (1.3) 2 (2.1)
Streptococcus pneumoniae 16 (10.6) 16 (16.5)
Other 5 (3.3) 4 (4.1)
MRSA, methicillin-resistant S. aureus; NA, not available (the questionnaire did not
ask about encephalopathy in adults).
a Age 18 years.
b Type of bacterial complication is not mutually exclusive.
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acquired pneumonia during the 2006–2007 inﬂuenza season, 47%
were found to have a concurrent viral infection, and of these, 33%
were conﬁrmed as having inﬂuenza. Of the patients with proven
MRSA pneumonia, 51% died, reﬂecting the high virulence and
invasiveness of such staphylococcal infections.
As previously described, rates of bacterial pneumonia reported
during the 2009–10 H1N1 pandemic were lower than those
previously observed;8,54 however, in fatal cases, secondary
bacterial co-infection was reported in 13–55% of patients.8,18,55
In an analysis of lung tissue specimens from 77 patients with
conﬁrmed H1N1 inﬂuenza A between May and August 2009, the
most common pathogens were S. pneumoniae (10 cases), S. aureus
(seven cases, ﬁve of which were MRSA), S. pyogenes (six cases),
Streptococcus mitis (two cases), H. inﬂuenzae (one case), and
multiple pathogens (four cases).17 The ﬁndings in this reportFigure 5. Examples of pathophysiological interactions between inﬂuenza and bacte
permission from the reference cited.).underscored the importance of managing patients with inﬂuenza
who also may have bacterial pneumonia with both empiric
antibacterial therapy and antiviral medications. In regions with a
high MRSA prevalence, the combination of inﬂuenza A (H1N1)
infection with secondary MRSA infections is of special importance.
3.1. Pathogenesis of secondary bacterial infections in inﬂuenza
There is strong and consistent evidence of epidemiologically and
clinically important interactions between inﬂuenza and secondary
bacterial respiratory pathogens. Potential mechanisms for synergies
between viral and bacterial infection include: virus destruction of
respiratory epithelium, which may increase bacterial adhesion;
inﬂuenza virus neuraminidase activity, which might also enhance
bacterial adherence; inﬂammatory responses to viral infection that
may upregulate expression of molecules utilized as receptors by
bacteria; virus-induced, immunosuppression-promoting bacterial
superinfections;56 and synthesis of virus-activating bacterial
proteases.57 Some of the key pathophysiological effects are shown
in Figure 5.
Evidence from in vitro studies has demonstrated the lethal
synergism between inﬂuenza virus and S. pneumoniae. Inﬂuenza
virus infection has been shown to prime for the development of
lethal pneumococcal pneumonia and bacteremia in a dose-
dependent fashion in a mouse model.58 The greatest synergy
occurred with an interval of 7 days between the administration of
virus and bacteria, and pathologic ﬁndings were more extensive
and more severe than seen with classic lobar pneumonia. Both
inﬂuenza-induced neutrophil dysfunction and neutrophil-inde-
pendent mechanisms, such as enhanced cytokine production, have
been shown to contribute to enhanced susceptibility to a
secondary S. pneumoniae infection.59 Elevated intrapulmonary
levels of inﬂammatory cytokines/chemokines, type-1 T-helper cell
cytokines and toll-like receptors, and the related mitogen-
activated protein kinase (MAP) signaling molecules were observed
in mice inoculated with both inﬂuenza virus and S. pneumoniae
with an interval of 2 days, suggesting that immune mediators play
an important role in the pathology of co-infection through toll-like
receptors/MAP kinase pathways.60
Another proposed mechanism that predisposes the host to
pneumococcal pneumonia is inﬂuenza-induced type I interferonrial respiratory pathogens and various clinical expressions.48 (Reproduced with
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appreciated that inﬂuenza infection can decrease tracheal
mucociliary velocity and initial pneumococcal clearance which,
in a mouse model, was shown to result in increased pneumococcal
burden as early as 2 h after pneumococcal infection.62
More recently, a study showed that such post-viral effects are
persistent. Sustained desensitization of lung sentinel cells to toll-
like receptor ligands lasts for several months after resolution of
inﬂuenza and is associated with reduced chemokine production
and nuclear factor kappa B (NF-kB) activation in alveolar
macrophages.63 This results in reduced neutrophil recruitment
and correlates with heightened bacterial load during secondary
respiratory infections. It is therefore important to recognize that
the inﬂuenza infection initiates a complex cascade that progresses
over time. The cascade evolves from innate to adaptive immune
mechanisms before moving on to repair and resolution, and it is at
this stage, around day 12, that the lungs are most vulnerable to
secondary bacterial sepsis.64 These features are consistent with the
observed epidemiology of invasive pneumococcal disease in
children; correlation with previous inﬂuenza infection is statisti-
cally signiﬁcant over the ﬁrst 4 weeks, becoming less strong
between weeks 2 and 4.65
Overall, there is ample evidence that the inﬂuenza virus alters
the host in a way that predisposes it to enhanced adherence,
invasion, and infection induction by S. pneumoniae. The key factor
is viral-facilitated bacterial access to receptors through epithelial
damage, exposure or upregulation of existing receptors, or
induction of the epithelium regeneration response following
cytotoxic damage.58 The clinical relevance of these ﬁndings is
highlighted by a recent study by Palacios et al., who found that the
antemortem presence of S. pneumoniae in nasal swabs of patients
with 2009 H1N1 inﬂuenza A was strongly associated with severe
disease and death.66
The mechanisms underlying S. aureus co-infection have also
been studied in vivo. Viral infections in the respiratory tract favor
growth conditions for bacteria and it is now known that some S.
aureus strains secrete a protease responsible for the proteolytic
cleavage of the inﬂuenza hemagglutinin (HA), critical for the virus
infectivity.57 Host proteases also play a role in the activation of
viral fusion glycoproteins, required for entry into host cells. A
trypsin-like protease identiﬁed in rat lung tissue showed dose-
dependent HA cleavage activity.67
4. The treatment of post-inﬂuenza bacterial pneumonia
Although post-inﬂuenza bacterial pneumonia is a well recog-
nized entity, there are very few publications describing or
reviewing the appropriate management of this condition. Perhaps
this is not surprising, given the rare occurrence of pandemics and
hence the difﬁculties in accumulating signiﬁcant cohorts of
patients to evaluate during conventional seasonal ﬂu periods.
This section will focus on approaches to sepsis management and
aspects of such cases that are peculiar to the inﬂuenza setting,
recognizing that critical care and other supportive therapeutic
interventions such as physiotherapy have important parts to play.
4.1. Review of guidelines
A review of the available guidelines on the management of
hospital- and community-acquired pneumonia uncovers very little
in the way of guidance for the management of post-inﬂuenza
bacterial pneumonia.68–74 Only two sets of guidelines70,72 directly
address the issue of inﬂuenza. The ﬁrst of these focused on H5N1,
the threat prevalent at the time of development, and recom-
mended that patients with this suspected infection should be
treated with oseltamivir and antibacterials targeted at S. aureusand S. pneumoniae, the most common pathogens associated with
post-inﬂuenza bacterial pneumonia.72 In 2007, the UK Department
of Health, in collaboration with learned societies and others,
provided guidance against an inﬂuenza pandemic.70 Nevertheless,
at the start of the most recent pandemic, the Department of Health,
in the face of signiﬁcant professional concerns, revised its earlier
risk-assessed approach to antimicrobials and recommended that
antibacterials should be deployed for all patients with inﬂuenza
admitted to hospital, regardless of disease severity or whether
bacterial infection was suspected.75 The Infectious Diseases
Society of America (IDSA) published recommendations on their
website in the form of Frequently Asked Questions regarding
treatment of the 2009 H1N1 inﬂuenza A and its complications.
They included antibacterial agents typically recommended for
community-acquired pneumonia in hospitalized patients, with
additional coverage for MRSA if the clinical presentation or a Gram
stain of respiratory secretions suggested the possibility of MRSA.76
In view of very real concerns about the potential for overuse of
antimicrobial drugs and the risks attached to such abuses, it would
appear reasonable to apply the same risk assessment approaches
and therapeutic interventions to patients with post-inﬂuenza
bacterial pneumonia that would be considered for other causes of
community-acquired pneumonia (while recognizing the lack of an
evidence base for such a conclusion). The issues for this condition
then become whether there are special treatment implications
related to the background viral etiology of the acute bacterial
pneumonia.
As previously described, evidence demonstrates that the
spectrum of bacterial pathogens involved in post-inﬂuenza
bacterial pneumonia has remained relatively constant over time
in terms of the species involved, although these now reﬂect the
resistance epidemiology of the geographical areas in which they
present. Empiric antibiotic prescribing should therefore reﬂect the
local surveillance intelligence of susceptibility patterns against the
spectrum of pathogens related to this condition, mainly S. aureus
and S. pneumoniae.
4.2. The role of neuraminidase inhibitors (NAIs)
As summarized above, there is considerable evidence that the
viral background of post-inﬂuenza bacterial pneumonia inﬂuences
disease characteristics. Therefore, the role of NAIs has been
assessed in terms of early, late, and second-phase treatment.
Early and late treatment considerations relate to the potential
role that NAI therapy may have in preventing subsequent bacterial
pneumonia. For maximal effect, NAI therapy is recommended to
commence within the ﬁrst 48 h of the inﬂuenza onset. Few studies
have been large enough to evaluate the impact of early initiation of
NAI therapy on subsequent bacterial complications associated
with inﬂuenza infection. However, a review of several studies22–24
and a pooled analysis25 demonstrate a clear trend toward a lower
rate of bacterial complications, including pneumonia, in patients
with conﬁrmed inﬂuenza infection receiving early NAI treat-
ment.24,77 In the pooled intention-to-treat analysis,25 19 of 1063
subjects receiving placebo were diagnosed with pneumonia (1.8%),
and nine of 1350 subjects receiving oseltamivir (0.7%) were
diagnosed with pneumonia (p < 0.02, calculated by authors). A
later systematic review and meta-analysis of randomized con-
trolled trials of NAIs in the treatment and prophylaxis of inﬂuenza
in children showed a statistically signiﬁcant reduction in otitis
media in children aged 1–5 years and an overall reduction in
antibiotic use, though not statistically signiﬁcant.77 A cumulative
case–control study using a multivariable model demonstrated
that, relative to controls not admitted to hospital, the severity of
illness among patients infected with pandemic H1N1 inﬂuenza
was associated with the length of time from onset of symptoms to
Table 3
Protein synthesis inhibiting antibacterial drugs
Aminoglycosides
Gentamicin, tobramycin, amikacin, netilmicin, streptomycin
Tetracyclines
MLS group
Macrolides, lincosamides (e.g., clindamycin), streptogramins
Chloramphenicol
Fusidic acid
Rifampin
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underlying medical comorbidities.78 Although there is only limited
evidence regarding the use of early NAI treatment in the
prevention of inﬂuenza-related bacterial pneumonia, particularly
in at-risk groups, the available data suggest a protective effect.
The possible beneﬁts of late NAI administration, i.e., after 48 h
but during the ﬁrst 5 days of the acute inﬂuenza illness, in the
prevention of bacterial complications following inﬂuenza were
ﬁrst described in a mouse model with secondary pneumococcal
pneumonia after inﬂuenza. The results showed that treatment
with oseltamivir improved survival from 0% to 75% when therapy
was initiated between 2 and 3 days after viral infection, but the
survival rate was approximately 30% when therapy was delayed
for up to 5 days after infection with the inﬂuenza virus. Treatment
with the M2 ion-channel inhibitor rimantadine had no effect on
survival.79 Furthermore, a prospective cohort study of patients
(n = 310) admitted to Ontario hospitals with laboratory-conﬁrmed
inﬂuenza showed a signiﬁcantly reduced mortality rate in patients
who received oseltamivir therapy within 96 h of symptom onset
(odds ratio (OR) 0.21, 95% conﬁdence interval (CI) 0.06–0.80);
however, the difference in mortality was not signiﬁcant when
therapy was started more than 48 h after symptom onset (OR 0.24,
CI 0.05–1.14).80 Despite the lack of prospective randomized clinical
data to support these results, late NAI administration has been
recommended by the IDSA76 and has been adopted in some
centers, especially for at-risk groups, with the aim of reducing
secondary bacterial complications. The understanding of the
pathogenesis of bacterial pneumonia in this setting coupled with
the safety of NAIs and the positive results from animal studies has
led to one set of guidelines advocating ‘late’ use of NAIs in its
recommendations in speciﬁc circumstances, but not for the
prevention of bacterial pneumonia.72
Finally, there is second-phase NAI administration, when
antiviral therapy is administered together with antibacterial
therapy at the start of the pneumonia treatment. Pre-clinical
models have shown elevated viral titers during bacterial super-
infections that may be associated with increased complications. It
has been hypothesized that there could be beneﬁts to be gained
from adding antiviral therapy to antibacterial agents to diminish
the associated secondary viral burst during such a combined
infection.81 There are no robust animal or human data to support
this approach, but its theoretical basis is sound.
The use of NIAs has been considered a key strategy for limiting
the impact of inﬂuenza despite concerns for the emergence of
resistance. Combination therapy could potentially reduce the
development of resistant strains. However, a randomized con-
trolled trial showed that an oseltamivir–zanamivir combination
was signiﬁcantly less effective, both virologically and clinically,
than oseltamivir monotherapy, and not signiﬁcantly more effective
than zanamivir monotherapy in adults with seasonal inﬂuenza A.82
It is hoped that the upcoming availability of new promising
anti-inﬂuenza agents, such as the NAIs peramivir and laninamivir,
and the RNA polymerase inhibitor favipiravir, will have a beneﬁcial
impact on the management of inﬂuenza-related pneumonia.
4.3. Role of antibacterials—protein synthesis inhibitors (PSIs)
In assessing the potential role of antibacterial drugs in the
management of post-inﬂuenza bacterial pneumonia, it is again
relevant to consider whether the viral milieu of this infection
requires special considerations. As described previously, inﬂam-
matory processes associated with bacterial sepsis in the lungs are
superimposed on an already active battleground of anti- and pro-
inﬂammatory activity. Clearly, the inﬂammatory response is a key
element in combating bacterial infection, but too much stimula-
tion, as a result of the combination of bacterial and viral triggers,might lead to lung damage and increased mortality. In cases where
an intense inﬂammatory reaction is already underway, such as
during inﬂuenza, the augmented response related to the bacterial
superinfection may be more detrimental than curative. Therefore,
antibacterial therapy should be targeted at contributing as much as
possible to the attainment of a balance of anti- and pro-
inﬂammatory activity necessary for resolution of infection and
survival.81 This hypothesis has led to interest in the role of protein
synthesis inhibitors (PSIs) (Table 3) as potential antibacterial
agents aimed at reducing bacterial toxin production and prevent-
ing rapid bacterial lysis, hence minimizing the impact of disrupting
bacterial cell wall release-driven pro-inﬂammatory components
that trigger inﬂammation.
In a rabbit model of pneumococcal meningitis, treatment with
the non-lytic PSI antibiotic rifampin, compared with ceftriaxone,
resulted in a decreased release of bacterial products and
diminished accumulation of host cytokines into the cerebrospinal
ﬂuid, which was associated with reduced mortality.83 The
potential impact of the inﬂammatory response resulting from
bacterial lysis has been reported in a study of 109 children with
pneumococcal meningitis treated with a combination of the cell
wall lytic agents vancomycin plus either ceftriaxone or cefotax-
ime.84 Outcomes indicated that vancomycin given within 2 h of the
ﬁrst dose of cephalosporin conferred no clinical beneﬁt and, in fact,
was associated with a substantially increased risk of hearing loss.
More recently, a mouse model was used to investigate the
hypothesis that treatment with a PSI would improve outcomes by
reducing the inﬂammatory response in the context of pneumonia
where infection with inﬂuenza virus was followed by superinfec-
tion with S. pneumoniae.85 Survival rates in this study were 56% on
ampicillin treatment, 82% on clindamycin, 80% on clindamycin
with ampicillin added at 24 h, and 92% on azithromycin alone. It
was also shown that the tumor necrosis factor alpha (TNF-a)
response associated with clindamycin therapy was less than that
observed with controls and signiﬁcantly lower than that elicited
with ampicillin treatment. This occurred despite the fact that the S.
pneumoniae lung load at 24 h was effectively unaltered from the
start of sepsis for clindamycin but was signiﬁcantly reduced for
ampicillin, with a statistically signiﬁcant difference from the
elevated level associated with controls. Although there are no
corresponding data in human subjects, these ﬁndings do support
the initiation of antibacterial treatment with a PSI. Such an agent
would need to be selected according to the local surveillance
patterns of the likely pathogens described above.
There are also reports of immunomodulatory effects of
macrolides on inﬂuenza and these may have a bearing on the
treatment inﬂuenza-associated pneumonia. The survival rate of
mice infected with a lethal dose of inﬂuenza virus increased with
the administration of erythromycin in a dose-dependent manner,
which resulted in reduced production of interferon gamma (IFN-
g), inhibition of inﬂammatory-cell inﬁltration, decreased levels of
nitrite/nitrate in the serum, and reduction of the nitric oxide (NO)
synthase-inducing potential in the lungs, without signiﬁcantly
affecting the virus yield.86 Another study revealed the inhibitory
effects of clarithromycin on human tracheal epithelial cells
infected with the inﬂuenza virus. The antimicrobial agent reduced
Table 4
Antimicrobials in the management of post-inﬂuenza bacterial pneumonia
Antimicrobial type Antimicrobial Agent Timing Purpose
Antiviral Neuraminidase inhibitor Early (48 h of viral onset) Prevention of bacterial pneumonia
Late (within 5 days of viral onset) Prevention of bacterial pneumonia
Second phase (with antibacterial
treatment at pneumonia onset)
Management of combined viral/bacterial
infection to improve outcome
Antibacterial Protein synthesis
inhibitor (PSI)
At onset of treatment Minimization of the adverse consequences
of an over-deployed immune response
Cell wall active agent At onset or 24 h after start
of treatment
Optimization of clinical outcomes in
combination therapy with a PSI agent
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inﬂammatory cytokines.87 In contrast, the concomitant adminis-
tration of corticosteroids to critically ill patients with pandemic
inﬂuenza A/H1N1 2009 was signiﬁcantly associated with higher
mortality and susceptibility to secondary bacterial pneumonia or
invasive fungal infection,88 and an observational prospective
cohort study revealed that immunomodulatory therapies (corti-
costeroids, macrolides, and statins) did not prevent the develop-
ment of severe disease in adults with 2009 H1N1 complicated by
pneumonia.89
There is additional debate over whether a PSI should be used
alone or together with another antibacterial agent. Combination
antibacterial treatment is often recommended in the management
of acute pneumonia, although its mechanism of beneﬁt is not
clearly understood. For patients with more severe diseases,
atypical pathogens are a less common risk; therefore, combination
therapy with a macrolide is often contemplated in the context of
improved clinical outcomes related to an immunomodulatory
effect. Most of the studies showing positive results for combination
therapy in opposition to monotherapy involved the use of a b-
lactam/macrolide combination versus a b-lactam alone, which
prevents robust extrapolation to other PSIs.90–94
Although the absence of high-quality, prospective, randomized
controlled studies evaluating combination therapy against deﬁned
bacterial pathogens in speciﬁc patient groups continues to foster
debate about its potential beneﬁts, it is in severe pneumonia
caused by S. pneumoniae, especially when associated with
bacteremia, that this evidence is strongest.95,96 Since this
microorganism is one of the pathogens most frequently associated
with post-inﬂuenza acute bacterial pneumonia, combination
treatment, tailored according to clinical response and microbiolo-
gy results, is a reasonable initial empiric approach. Caution should
be exerted, though, as results of a descriptive study of antimicro-
bial susceptibility in isolates from the lower respiratory tract of
patients with inﬂuenza-like illness showed that susceptibility to
macrolides was lower than that to tetracycline or co-amoxiclav.97
New evidence suggests that the use of a PSI with a bacterial cell
wall lysis agent may be more effective than two drugs working
individually to disrupt bacterial integrity. In a human retrospective
observational report, the use of initial empiric antimicrobial
therapy with a b-lactam and a ﬂuoroquinolone was associated
with an increased short-term mortality for patients with severe
pneumonia when compared with other guideline-concordant
antimicrobial regimes.98 However, there is no available intelli-
gence to assess whether, in a combination approach, the drugs
should be administered concomitantly or sequentially with the PSI
given ﬁrst.
Although there is promising observational evidence supporting
the use of macrolides in severe community-acquired pneumonia,
the beneﬁts of PSIs remain unproven, speciﬁcally in the subpopula-
tion group of bacteremic pneumococcal pneumonia. Despite the
absence of prospective, randomized controlled clinical studies
comparing a b-lactam/macrolide combination with non-macrolide
monotherapy, some experts support obligatory macrolide therapyin community-acquired pneumonia with physiological compro-
mise, especially those with or deemed at risk for septic shock or
mechanical ventilation.95
5. Conclusions
Inﬂuenza predisposes patients to subsequent bacterial infection
through a variety of local and systemic effects, including direct
damage to respiratory epithelium and effects on local and systemic
immune function. Notwithstanding yearly variations, good evi-
dence indicates that mortality related to inﬂuenza is mostly due to
secondary bacterial pneumonia, although the 2009 H1N1 pan-
demic may have been an exception to this rule. The available data
suggest that during non-pandemic years, approximately 1% of
individuals who develop inﬂuenza will develop secondary
bacterial pneumonia, with a higher risk for patients with
comorbidities and during some pandemic years. Despite much
professional and public interest in inﬂuenza and its complications
over the last 50 years, there remains a dearth of high-quality
clinical trials to inform optimal management approaches. There is
an urgent need to rectify this deﬁciency, and the normal seasonal
ﬂu distribution offers an appropriate base on which to ground this
work. When assessing treatment options, both antivirals and
antibacterials must be considered (Table 4), and their selection has
to be based upon a clear understanding of the way in which their
mechanisms of action intervene in the pathogenesis of post-
inﬂuenza acute bacterial pneumonia. Current data suggest that the
use of NAIs in prevention and treatment may provide additional
beneﬁt when used with PSI antibacterials as part of an antimicro-
bial combination therapy. However, further studies are necessary
to support their routine clinical use. In addition, since S.
pneumoniae and S. aureus are the most common bacterial
pathogens in post-inﬂuenza bacterial pneumonia, there should
be strong consideration for initial empiric coverage of these
organisms, taking into account local antibiotic resistance patterns.
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